<DOC>
	<DOCNO>NCT00777296</DOCNO>
	<brief_summary>A major factor respiratory health CF subject acquisition chronic Pseudomonas aeruginosa infection . The infection rate P. aeruginosa increase age age 18 year , 80 % CF subject U.S. infected . Liposomal Amikacin Inhalation ( Arikayce™ ) sterile aqueous liposomal suspension consist amikacin sulfate encapsulate liposomes . This formulation amikacin maximize achievable dose delivery lung subject infect via nebulizer . Because liposome particle small enough penetrate diffuse sputum bacterial biofilm , deposit drug close proximity bacterial colony ( Meers , et al. , 2008 ) ( Clancy , et al. , 2013 ) , thus improve bioavailability amikacin infection site . The clinically achievable dos amikacin LAI formulation effectively increase half-life drug lung , decrease potential systemic toxicity . LAI offer several advantage current therapy treat CF subject chronic infection cause P. aeruginosa .</brief_summary>
	<brief_title>Multidose Safety Tolerability Study Dose Escalation Liposomal Amikacin Inhalation ( ARIKAYCE™ )</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) genetic disease result mutation 230 kb gene chromosome 7 know cystic fibrosis transmembrane conductance regulator ( CFTR ) . Study subject CF manifest pathological change variety organs express CFTR . The lung frequently affect , sequelae chronic infection airway inflammation . The principal goal treatment subject CF slow chronic deterioration lung function . This Phase 2a study safety , tolerability 28 day daily dose two dose ( 280mg , 560 mg ) cohorts Arikayce™ versus placebo . Study subject randomize receive either study drug placebo ( 1.5 % NaCl ) inhalation via PARI eFlow nebulizer . Cohort 1 ( 280mg ) complete 28 day daily dose Arikayce™ 14 day post dose safety evaluation Safety Committee ( DSMB ) initiation enrollment Cohort 2 ( 560mg ) . Cohort 2 complete 28 day daily dose , 14 day post dose safety assessment DSMB evaluate safety data . All study patient follow safety , pharmacokinetics , clinical microbiologic activity 28 day post completion study treatment . The total study period 56 day , screen visit occur within precede 14 day prior randomization . Patients clinically evaluate first 48 hour post-randomization , weekly 28 day treatment period , follow visit study day 35 , 42 , 49 56 day determine safety , tolerability , pharmacokinetics ( PK ) , clinical , microbiologic activity . Clinical laboratory parameter , audiology testing , clinical adverse event pulmonary function evaluate study subject order determine qualitative quantitative safety tolerability Arikayce™ compare Placebo . Serum , urine , sputum specimen collect periodic interval assess PK . Additionally ; sputum sample collect determine change bacterial density . Pulmonary function test CFQ-R measurement assess select time point throughout study . DSMB recommend amendment main study evaluate safety efficacy additional cycle treatment Arikayce™ . All patient randomize main study , compliant study protocol , continue meet study eligibility criterion consent participate open-label extension evaluate safety , tolerability efficacy 560 mg daily dose Arikayce™ administer six cycle eighteen month . Each cycle comprise 28 day treatment follow 56 day treatment . The total extension period 518 day ( 74 week , 18 month ) . Clinical laboratory parameter , audiology testing , clinical adverse event pulmonary function evaluate study subject order determine long term safety , tolerability , efficacy Arikayce™ . Serum specimens collect periodic interval assess PK safety . Additionally , sputum sample collect determine change bacterial density . Pulmonary function test CFQ-R measurement assess select time point throughout study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Written inform consent obtain patient designate legal guardian prior performance study related procedure . Male female study subject ≥6 year age old Confirmed diagnosis CF History chronic infection P. aeruginosa Study subject must produce screen specimen positive growth P. aeruginosa FEV1 ≥ 40 % predict Screening SaO2 ≥ 90 % Screening breathing room air Ability comply study medication use , study visit study procedure judge investigator Ability produce sputum willing undergo induction produce sputum clinical evaluation Clinically stable evidence acute upper low respiratory tract infection history pulmonary exacerbation within 4 week prior screen Administration investigational drug within 8 week prior Screening Emergency room visit hospitalization CF respiratoryrelated illness within 4 week prior screen History alcohol , medication illicit drug abuse within 1 year prior screen History lung transplant Female childbearing potential lactating practice acceptable method birth control ( e.g. , abstinence , hormonal barrier method , partner sterilization , IUD ) Positive pregnancy test Use antipseudomonal anitbiotics ( IV antibiotic , inhalation antibiotic , oral fluoroquinolones ) within 28 day prior screen Initiation chronic therapy ( i.e . TOBI® , highdose ibuprofen , rhDNase , macrolide antibiotic ) within 28 day prior screen History sputum throat swab culture yield Burkholderia cepacia within 2 year Screening History mycobacterial Aspergillus infection History biliary cirrhosis portal hypertension , splenomegaly History daily , continuous oxygen supplementation requirement 2 L/min night Change chest xray screening ( within 3 month prior screen )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Respiratory Infections</keyword>
	<keyword>Pulmonary Cystic Fibrosis</keyword>
	<keyword>CFTR</keyword>
</DOC>